Record mula sa primary source
Decision-gradeTopline na resulta
Travere: Topline data ng Phase 3 HARMONY ng pegtibatinase sa 2H 2027
Kinumpirma ng 8-K ang patuloy na pivotal Phase 3 HARMONY Study sa classical HCU na nasa tamang takbo, na may topline data na inaasahan sa ikalawang kalahati ng 2027. Ito ang susunod na pangunahing klinikal na milestone para sa asset, na inilalagay bilang potensyal na unang disease-modifying therapy para sa HCU.
Mahahalagang fact
- Na-file
- Ago 4, 2026, 08:05 PM
- Kaganapan
- Topline na resulta
- Direksyon
- Neutral
- Kumpanya
TVTXTravere- Asset
- pegtibatinase
- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
Sipi mula sa source
EX-99.1 2 a2026q2_8-kxex991.htm EX-99.1 Document Exhibit 99.1 Contact: Investors: Media: 888-969-7879 888-969-7879 IR@travere.com mediarelations@travere.com Travere Therapeutics Reports Second Quarter 2026 Financial Results Strong FSGS launch and continued IgAN growth drive robust FILSPARI demand; 2,012 new PSFs received during the second quarter U.S. net product sales of FILSPARI grew 96% year-over-year to $141 million Enrollment of pegtibatinase Phase 3 HARMONY Study in HCU continues; Topline data expected in 2H 2027 In-licensing of civorebrutinib expands long-term growth opportunities in multiple immune-mediated rare kidney diseases SAN DIEGO, August 4, 2026 – Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its second quarter 2026 financial results and provided a corporat